| dc.contributor.author | He, X. | |
| dc.contributor.author | Quek, R. G. | |
| dc.contributor.author | Gogishvili, M. | |
| dc.contributor.author | Gullo, G. | |
| dc.contributor.author | Rietschel, P. | |
| dc.contributor.author | Bondarenko, I. | |
| dc.contributor.author | Sezer, A. | |
| dc.contributor.author | Kilickap, S. | |
| dc.contributor.author | GÜMÜŞ, MAHMUT | |
| dc.contributor.author | ÖZGÜROĞLU, MUSTAFA | |
| dc.date.accessioned | 2022-07-04T15:58:22Z | |
| dc.date.available | 2022-07-04T15:58:22Z | |
| dc.identifier.citation | Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., He X., Gullo G., Rietschel P., Quek R. G. , "Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation", ANNALS OF ONCOLOGY, cilt.33, 2022 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_cce2a7b8-f5e2-43d6-af54-4c8f44a50483 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/184723 | |
| dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/cce2a7b8-f5e2-43d6-af54-4c8f44a50483/file | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2022.02.139 | |
| dc.language.iso | eng | |
| dc.subject | Onkoloji | |
| dc.subject | Oncology | |
| dc.subject | Health Sciences | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.title | Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation | |
| dc.type | Makale | |
| dc.relation.journal | ANNALS OF ONCOLOGY | |
| dc.contributor.department | Dnipro State Medical University , , | |
| dc.identifier.volume | 33 | |
| dc.contributor.firstauthorID | 3407239 | |
